The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).
 
M. Rizwan Rizwan-ul-Haq Khawaja
Consulting or Advisory Role - Red Arrow Therapeutics
 
Abdul Rafeh Naqash
Honoraria - NGM Biopharmaceuticals
Consulting or Advisory Role - foundation me
Travel, Accommodations, Expenses - American Society for Radiation Oncology; ASCO; Binacea; Foundation Medicine; Jazz Pharmaceuticals (Inst); Society for Immunotherapy of Cancer
 
Reva Schneider
No Relationships to Disclose
 
Aditi Shastri
Honoraria - NACE and PeerView
Consulting or Advisory Role - Gilead Sciences; Janssen; Kymera; Rigel
Research Funding - Kymera
 
Maximilian Stahl
Consulting or Advisory Role - Boston Consulting Group; Clinical Care Options; Curis Oncology; GlaxoSmithKline; Haymarket; Kymera; Novartis; Sierra Oncology
 
Justin C Moser
Honoraria - Caris Life Sciences; Daiichi Sankyo/Lilly; TGen
Consulting or Advisory Role - Adagene; Amunix; Boxer Capitol; Bristol Myers Squibb Foundation; Genome Insight; Imaging Endpoints; Incyte; IQvia; Novotech; Oberland Capital; Red Arrow Therapeutics; Thirona Biosciences; Werewolf Therapeutics (Inst)
Speakers' Bureau - Caris Life Sciences; Castle Biosciences; Immunocore
Research Funding - Adaptimmune (Inst); Agenus (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); BioEclipse Therapeutics (Inst); Fate Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); IDEAYA Biosciences (Inst); ImmuneSensor Therapeutics (Inst); Iovance Biotherapeutics (Inst); Istari Oncology (Inst); Nektar (Inst); Novocure (Inst); Repertoire Immune Medicines (Inst); Rubius Therapeutics (Inst); Senhwa Biosciences (Inst); Simcha Therapeutics (Inst); Storm Therapeutics (Inst); Synthorx (Inst); T-Scan Therapeutics (Inst); Trishula Therapeutics (Inst); University of Arizona (Inst); Werewolf Therapeutics (Inst); Y-mAbs Therapeutics (Inst)
Other Relationship - Caris Life Sciences
 
Nagla Fawzy Abdel Karim
Stock and Other Ownership Interests - Abbott Biotherapeutics (I)
Consulting or Advisory Role - Amgen; Bayer; Bristol Myers Squibb Foundation; G1 Therapeutics; Jazz Pharmaceuticals; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb/Pfizer (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst)
 
Yazan Madanat
Honoraria - Blueprint Medicines; Bristol Myers Squibb; GERON; Kura Oncology; MorphoSys; Novartis; OncLive/MJH Life Sciences; Rigel; Sierra Oncology; SOBI; Stemline Therapeutics; Taiho Oncology
Consulting or Advisory Role - Geron
Travel, Accommodations, Expenses - Blueprint Medicines; MorphoSys
 
Brian Andrew Jonas
Consulting or Advisory Role - Abbvie; BMS; Daiichi Sankyo; Genentech; Gilead Sciences; GlycoMimetics; Kura Oncology; Kymera; Rigel; Servier; Syndax
Research Funding - Abbvie (Inst); Amgen (Inst); Aptose Biosciences (Inst); AROG (Inst); Biomea Fusion (Inst); BMS (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immune-Onc Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kymera (Inst); Loxo (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Treadwell Therapeutics (Inst)
Travel, Accommodations, Expenses - Rigel
Other Relationship - Gilead Sciences; GlycoMimetics
 
Eytan Stein
Stock and Other Ownership Interests - Auron Therapeutics
Consulting or Advisory Role - Abbvie; Agios; Aptose Biosciences; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Calithera Biosciences; CTI BioPharma Corp; Daiichi Sankyo; Debiopharm Group; Foghorn Therapeutics; GEMoaB; Genentech; Genesis Pharma; Gilead Sciences; Immunogen; Janssen; Jazz Pharmaceuticals; Jnana Therapeutics; Menarini; Neoleukin Therapeutics; Novartis; OnCusp Therapeutics; Ono Pharmaceutical; PinotBio; SERVIER; Syndax
Research Funding - agios (Inst); Bayer (Inst); BioTheryX (Inst); Bristol-Myers Squibb/Celgene (Inst); Cleave Biosciences (Inst); Eisai (Inst); Foghorn Therapeutics (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); Prelude Therapeutics (Inst); SERVIER (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst)
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - AstraZeneca
 
James K. McCloskey
No Relationships to Disclose
 
Ashwin Gollerkeri
Employment - Beam Therapeutics (I); Kymera
Stock and Other Ownership Interests - Beam Therapeutics (I); Kymera; Pfizer
Patents, Royalties, Other Intellectual Property - Receives royalties from Yale University on an antibody used in nephrology basic research. (I)
 
Rachelle Perea
Employment - Kymera
Stock and Other Ownership Interests - Kymera; Pfizer
 
Yogesh Chutake
Employment - Kymera
Stock and Other Ownership Interests - Kymera
Patents, Royalties, Other Intellectual Property - Kymera
 
Sagar Agarwal
Employment - Kymera
Stock and Other Ownership Interests - Kymera
 
Patrick Henrick
Employment - Kymera
Stock and Other Ownership Interests - Kymera
 
Kelvin Shi
Employment - Kymera
Stock and Other Ownership Interests - Kymera
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)